Dr. Reddy’s Laboratories Limited, has entered a definitive agreement to acquire the STUGERON® portfolio from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, for USD 50.5 million. The acquisition includes popular brands Stugeron® FORTE and Stugeron® PLUS, along with associated assets, covering 18 markets across Asia-Pacific (APAC) and Europe, Middle East, and Africa (EMEA), with India and Vietnam identified as key markets.
This strategic move strengthens Dr. Reddy’s Central Nervous System (CNS) portfolio, particularly in the antivertigo segment, enabling the company to meet growing demand in both domestic and emerging international markets. The operations of the STUGERON® portfolio will be gradually transitioned to ensure smooth integration and continuity of business. Importantly, the acquisition is an arm’s length transaction, with Janssen Pharmaceutica NV not being a related party to Dr. Reddy’s or its promoter group, ensuring full transparency and compliance with regulatory standards.
With this acquisition, Dr. Reddy’s expands its global reach while diversifying its product lineup. The addition of STUGERON® allows the company to offer more comprehensive solutions in the antivertigo space, enhancing patient access to effective treatments. This move is expected to drive long-term growth, reinforce Dr. Reddy’s brand presence internationally, and unlock new opportunities for revenue in both established and emerging markets.
